Efficacy News and Research

RSS

Researchers assess the evidence basis for medications used to treat spine-related pain in older adults

Spine-related pain is increasingly common in older adults. While medications play an important role in pain management, their use has limitations in geriatric patients due to reduced liver and kidney function, comorbid medical problems and polypharmacy (the simultaneous use of multiple drugs to treat medical conditions).

28 Jun 2022

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.

28 Jun 2022

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Researchers assessed the in vivo effectiveness of monoclonal antibodies and directly acting antiviral agents against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages.

28 Jun 2022

Cell-based assay highlights differences in antibody neutralizing capacity for SARS-CoV-2 variants

A recent study by scientists at Celentyx Ltd, the University of Birmingham, and the University of Warwick and posted to the bioRxiv* preprint server illustrated a cell-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein attachment assay.

28 Jun 2022

A cancer patient who had SARS-CoV-2 for over eight months

In a recent study posted to the medRxiv* pre-print server, researchers in Israel described the case of a severely immunocompromised cancer patient who developed a chronic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

28 Jun 2022

Researchers analyze potential of niclosamide as a SARS-CoV-2 treatment

A recent study posted to the bioRxiv* preprint server assessed whether niclosamide could be employed in coronavirus disease 2019 (COVID-19) therapy.

28 Jun 2022

In 1st year of pandemic, COVID vaccines saved 20M lives

In a recent study published in The Lancet journal, researchers at Imperial College London quantified the impact of the coronavirus disease 2019 (COVID-19) vaccination programs in 185 countries and territories between December 8, 2020, and December 8, 2021.

28 Jun 2022

Innovative treatment reduces post-traumatic headache related disability, study finds

The first therapy to be developed specifically for post-traumatic headache significantly reduced related disability in veterans following a traumatic brain injury (TBI).

27 Jun 2022

Researchers investigate clinical epidemiological impact of Omicron among hospitalized COVID-19 patients

Researchers assessed the global impact of the emergence of the SARS-CoV-2 Omicron variant on COVID-19 clinical epidemiology among hospitalized patients.

27 Jun 2022

Breakthrough infection with pre-Omicron variant induces cross-neutralizing activity against Omicron

Researchers evaluated the neutralizing ability of sera from COVID-19 patients.

27 Jun 2022

Chemically modified rocaglates have a stronger effect against viral replication

Hepatitis E virus (HEV) is widespread, and so far there is no effective drug. In the search for one, the so-called rocaglates have come into focus: plant compounds that can inhibit the replication of viruses.

27 Jun 2022

Review and case study illustrates the challenges of monkeypox

A new paper published in Travel Medicine and Infectious Disease reviews the history of this disease in and outside Africa, with special reference to its clinical difficulties.

27 Jun 2022

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Researchers presented the PREVENT-19 phase 3 trial findings on the effectiveness of the NVX-CoV2373 adjuvanted, recombinant S nanoparticle vaccine.

27 Jun 2022

Antigenic differences between early SARS-CoV-2 variants

Researchers used antigenic cartography to quantify and visualize antigenic differences between multiple SARS‐CoV‐2 variants.

27 Jun 2022

LUCID: music, medicine, and machine learning

In this interview, News-Medical speaks to Zoë Thomson, Co-founder and Chief Innovation Officer of LUCID, about how music and machine learning are changing how we approach mental and neuropsychiatric health.

27 Jun 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

27 Jun 2022

Efficacy News and Research

Researchers assess the evidence basis for medications used to treat spine-related pain in older adults

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Cell-based assay highlights differences in antibody neutralizing capacity for SARS-CoV-2 variants

A cancer patient who had SARS-CoV-2 for over eight months

Researchers analyze potential of niclosamide as a SARS-CoV-2 treatment

In 1st year of pandemic, COVID vaccines saved 20M lives

Innovative treatment reduces post-traumatic headache related disability, study finds

Researchers investigate clinical epidemiological impact of Omicron among hospitalized COVID-19 patients

Breakthrough infection with pre-Omicron variant induces cross-neutralizing activity against Omicron

Chemically modified rocaglates have a stronger effect against viral replication

Review and case study illustrates the challenges of monkeypox

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Antigenic differences between early SARS-CoV-2 variants

LUCID: music, medicine, and machine learning

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

Five things to know now that the Supreme Court has overturned Roe V. Wade

Updated Cochrane Review: No evidence to support the use of ivermectin for treating COVID-19 infection

Scientists develop suitable human cell line for anti-SARS-CoV-2 drug screening

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News